한글목차

세계 표적 방사성의약품 시장의 미래는 표적 치료제 및 표적진단 시장에서 기회가 있고 유망한 것으로 전망되고 있습니다. 세계 표적 방사성의약품 시장은 2025-2031년까지 연평균 14.4%의 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 암 및 심혈관질환의 유병률 증가와 고령화 인구의 증가입니다.

• Lucintel의 예측에 따르면, 유형별로는 방사성 물질을 사용하여 암세포 및 기타 질병 조직을 선택적으로 표적화하여 치료하는 표적치료가 예측 기간 동안 높은 성장세를 보일 것으로 예상됩니다.
• 용도별로는 전립선암, 신경내분비종양, 림프종 등 암의 효과적인 치료로 표적 치료제가 높은 성장을 이룰 것으로 예측됩니다.
• 지역별로는 북미가 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.

표적 방사성의약품 시장의 새로운 동향

표적 방사성의약품 시장은 몇 가지 새로운 동향의 영향을 받아 미래 성장을 형성하고 있습니다. 이러한 추세에는 기술 발전, 규제 변화, 맞춤형 의료의 중요성 증가 등이 포함됩니다. 산업이 계속 발전함에 따라 이러한 추세는 치료 효과뿐만 아니라 신제품의 시장 출시 및 의료 시스템에 통합하는 방법에도 영향을 미칩니다.

• 테라노스틱스에 대한 관심 증가 : 진단용 방사성의약품과 치료용 방사성의약품을 결합한 테라노스틱스는 급성장하고 있는 추세입니다. 이 접근법을 통해 방사성동위원소로 암세포를 정확하게 표적화할 수 있어 맞춤형 치료 계획을 세울 수 있습니다. 진단과 치료를 동시에 할 수 있어 치료 효과를 높이고 부작용을 줄일 수 있습니다. 이러한 추세는 특히 종양학 분야에서 두드러지며, 전립선암 치료제인 플루빅토(Pluvicto)와 루테튬-177(Lutetium-177)과 같은 방사성의약품이 영상 진단과 치료 모두에 사용되면서 시장의 큰 성장을 견인하고 있습니다.
• AI와 머신러닝의 통합 : AI와 머신러닝의 방사성의약품 개발에 대한 적용이 진행되고 있습니다. 이러한 기술은 방사성의약품의 효능과 독성 프로파일을 예측하여 방사성의약품의 설계를 최적화하는 데 도움이 됩니다. 또한, AI를 활용한 툴은 방사성의약품의 제조 공정을 간소화하여 비용 절감과 정확도 향상을 실현하고 있습니다. 이러한 통합은 최적의 용량과 환자별 치료 요법을 식별하는 데 특히 유용하며, 궁극적으로 맞춤형 의료를 발전시키고 방사선 치료와 관련된 부작용을 줄일 수 있습니다.
• 암 표적 치료의 확대 : 암은 여전히 표적 방사성의약품의 주요 치료 대상이며, 치료 성적 향상을 위한 많은 개발이 이루어지고 있습니다. 신경내분비종양과 같이 치료가 어려운 암에 대한 방사성의약품의 증가로 시장이 확대되고 있습니다. 암세포에 국소적으로 방사선을 조사하는 알파 입자 치료와 같은 기술 혁신이 주목받고 있습니다. 이러한 시장 확대는 암 발병률의 증가와 보다 효과적이고 덜 침습적인 치료에 대한 수요 증가에 힘입어 방사성의약품은 암 치료의 중요한 도구로 자리매김하고 있습니다.
• 규제 발전 및 승인 절차 : 규제 당국, 특히 FDA와 EMA는 방사성의약품의 승인 절차를 간소화하고 새로운 치료법의 신속한 시장 진입을 촉진하고 있습니다. 예를 들어, 미국 FDA는 방사성의약품의 승인을 통해 유연한 경로를 제공하여 생명을 구하는 치료 과정을 신속하게 처리하고 있습니다. 이러한 추세는 연구부터 환자까지의 시간을 단축할 뿐만 아니라 방사성의약품 설계의 혁신을 촉진하고 있습니다. 규제 당국의 지원이 강화되면 시장의 신뢰가 높아져 전 세계적으로 이러한 치료법의 채택이 더욱 촉진될 것으로 기대됩니다.
• 세계 공동 연구 및 연구 이니셔티브 : 방사성의약품의 개발을 촉진하는 것은 국가 및 연구기관의 공동 연구입니다. 대학, 생명공학 기업, 의료 기관 등 민관 파트너십이 혁신을 가속화하고 있습니다. 국제 연구 컨소시엄은 새로운 동위원소 개발, 제조 기술 개선, 다양한 환자 집단에서 방사성의약품의 효능에 대한 이해도를 높이기 위해 노력하고 있습니다. 이러한 세계 접근 방식은 방사성의약품의 다양한 파이프라인을 육성하고, 전 세계 환자들이 최첨단 치료의 혜택을 누릴 수 있도록 돕고 있습니다.

이러한 추세는 기술 혁신을 촉진하고, 환자 치료 결과를 개선하며, 치료 비용을 절감함으로써 표적 방사성의약품 시장을 재편하고 있습니다. AI, 규제 발전, 세계 협력의 융합은 특히 암 분야에서 표적 치료의 개발과 가용성을 가속화하고 있습니다. 시장이 성장함에 따라 이러한 추세는 개인화된 정밀 기반 치료의 제공을 최적화하고, 궁극적으로 암 및 기타 복잡한 질병에 대한 의료 환경을 변화시킬 것으로 예상됩니다.

표적 방사성의약품 시장의 최근 동향

최근 몇 가지 동향은 규제 혁신에서 기술 혁신에 이르기까지 표적 방사성의약품 시장을 변화시키고 있습니다. 이러한 개발은 방사성의약품 치료의 정확성, 접근성, 유효성을 향상시켜 환자 예후 개선과 시장 성장의 길을 열어가고 있습니다.

• FDA의 플루빅토 승인 : 전립선암에 대한 플루빅토(177Lu-PSMA-617)의 승인은 암 분야 표적 방사성의약품에 있어 중요한 이정표가 될 것입니다. 이 새로운 치료법은 전립선암 세포를 특이적으로 표적으로 하는 분자와 방사성 입자를 결합하여 건강한 조직에 대한 손상을 줄여주는 치료법입니다. 이번 FDA의 승인은 전립선암에 대한 최초의 승인으로 진행성 전립선암 환자에게 새로운 희망을 주는 것입니다. 이 개발은 암 치료, 특히 특정 분자 표적을 가진 암에 대한 더 많은 혁신의 문을 열게 될 것입니다.
• 알파 입자 치료의 개발 : 악티늄225, 라듐223 등 알파 입자 치료는 다양한 암에 대한 유망한 치료법으로 떠오르고 있습니다. 이 치료법은 고도로 국소화된 방사선을 조사하기 때문에 주변의 건강한 조직에 대한 손상을 최소화하고, 기존 치료법에 저항성을 보이는 종양을 치료하는 새로운 접근법을 제시하고 있습니다. 알파 입자 치료 연구가 계속 발전하고 있는 가운데 표적 방사성의약품 시장은 특히 전이성 암 치료에서 큰 성장이 예상됩니다.
• 영상 및 진단 기술의 발전 : PET, SPECT 등 분자 영상 기술의 발전으로 표적 방사성의약품의 정확도가 크게 향상되고 있습니다. 이러한 이미징 기술을 통해 방사성의약품의 분포와 효과를 실시간으로 모니터링할 수 있어 질병 부위에 정확하게 방사성의약품을 투여할 수 있게 되었습니다. 이번 개발은 치료 결과를 극대화하기 위해 영상 진단 결과에 따라 치료를 조정할 수 있는 개인맞춤의료에 큰 의미가 있습니다.
• 생명공학기업과 제약기업의 파트너십 : 생명공학기업과 대형 제약기업과의 전략적 파트너십은 표적 방사성의약품의 개발을 가속화하고 있습니다. 예를 들어, 암 치료를 위한 새로운 방사성 표지 항체를 개발하기 위한 제휴는 표적 치료의 가능성의 한계를 넓히고 있습니다. 이러한 제휴를 통해 자원, 전문 지식, 임상 데이터를 공유할 수 있게 되었고, 궁극적으로 혁신적인 방사성의약품의 상용화를 가속화할 수 있게 되었습니다.
• 방사성동위원소 생산능력 확대 : 표적 방사성의약품에 대한 수요 증가에 대응하기 위해 각 업체들은 테크네튬-99m, 루테튬-177, 요오드-131 등 주요 방사성동위원소 생산능력을 확대하고 있습니다. 이 확장은 공급망 문제를 해결하고 임상 사용에 충분한 양의 동위원소를 확보하기 위한 것입니다. 제조 기술이 발전함에 따라 방사성의약품의 제조비용이 낮아져 더 많은 환자들이 이러한 치료법을 이용할 수 있게 될 것으로 예상됩니다.

이러한 주요 개발은 치료 접근성, 유효성, 정확성을 향상시켜 표적 방사성의약품 시장에 혁명을 일으키고 있습니다. FDA의 승인, 알파 입자 치료의 발전, 업계 관계자들 간의 파트너십 확대는 새로운 성장 기회를 창출하고 있습니다. 생산능력의 확대와 새로운 기술의 등장으로 시장은 지속적인 혁신을 이루며 세계 헬스케어에서 더욱 중요한 역할을 할 준비가 되어 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 산업 성장 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 유형별 세계의 표적 방사성의약품 시장

• 개요
• 유형별 매력 분석
• 표적 치료 : 동향과 예측(2019-2031년)
• 표적 진단 : 동향과 예측(2019-2031년)

제5장 용도별 세계의 표적 방사성의약품 시장

• 개요
• 용도별 매력 분석
• 표적 치료 : 동향과 예측(2019-2031년)
• 표적 진단 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 지역의 표적 방사성의약품 시장

제7장 북미의 표적 방사성의약품 시장

• 개요
• 미국의 표적 방사성의약품 시장
• 멕시코의 표적 방사성의약품 시장
• 캐나다의 표적 방사성의약품 시장

제8장 유럽의 표적 방사성의약품 시장

• 개요
• 독일의 표적 방사성의약품 시장
• 프랑스의 표적 방사성의약품 시장
• 스페인의 표적 방사성의약품 시장
• 이탈리아의 표적 방사성의약품 시장
• 영국의 표적 방사성의약품 시장

제9장 아시아태평양의 표적 방사성의약품 시장

• 개요
• 일본의 표적 방사성의약품 시장
• 인도의 표적 방사성의약품 시장
• 중국의 표적 방사성의약품 시장
• 한국의 표적 방사성의약품 시장
• 인도네시아의 표적 방사성의약품 시장

제10장 기타 지역의 표적 방사성의약품 시장

• 개요
• 중동의 표적 방사성의약품 시장
• 남미의 표적 방사성의약품 시장
• 아프리카의 표적 방사성의약품 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간의 경쟁 관계
  • 구매자의 교섭력
  • 공급 기업의 교섭력
  • 대체품의 위협
  • 신규 참여업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 유형에 의한 성장 기회
  • 용도에 의한 성장 기회
• 세계의 표적 방사성의약품 시장의 최신 동향
• 전략 분석
  • 신제품 개발
  • 인증과 라이선싱
  • 합병, 인수, 계약, 제휴, 합작투자

제13장 밸류체인 전체에 걸친 주요 기업 개요

• 경쟁 분석
• Novartis
• Bayer
• Lantheus
• Institute For Radioelements
• Radiomedix
• Curium Pharma
• Clarity Pharmaceuticals

제14장 부록

• 그림목차
• 표목차
• 조사 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• 당사에 대해
• 문의처

영문목차

The future of the global targeted radiopharmaceutical market looks promising with opportunities in the targeted therapy and targeted diagnosis markets. The global targeted radiopharmaceutical market is expected to grow with a CAGR of 14.4% from 2025 to 2031. The major drivers for this market are the increasing prevalence of cancer & cardiovascular disease and the growing aging population.

• Lucintel forecasts that, within the type category, targeted therapeutic is expected to witness higher growth over the forecast period due to use radioactive substances to selectively target and treat cancer cells or other disease tissues.
• Within the application category, targeted therapy is expected to witness the higher growth due to effective treatment of cancers such as prostate cancer, neuroendocrine tumors, and lymphoma.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Targeted Radiopharmaceutical Market

The targeted radiopharmaceutical market is influenced by several emerging trends, shaping its future growth. These trends include technological advancements, regulatory changes, and the increasing importance of personalized medicine. As the industry continues to evolve, these trends not only impact treatment efficacy but also the ways in which new products are brought to market and integrated into healthcare systems globally.

• Increased Focus on Theranostics: Theranostics, the combination of diagnostic and therapeutic radiopharmaceuticals, is a rapidly growing trend. This approach allows for precise targeting of cancer cells with radioactive isotopes, enabling personalized treatment plans. The ability to diagnose and treat simultaneously enhances treatment efficacy and reduces side effects. This trend is particularly prominent in oncology, where radiopharmaceuticals like Pluvicto for prostate cancer and Lutetium-177 are being used for both imaging and therapy, driving significant market growth.
• Integration of AI and Machine Learning: AI and machine learning are increasingly being applied to radiopharmaceutical development. These technologies help optimize the design of radiopharmaceuticals by predicting their effectiveness and toxicity profiles. AI-driven tools are also streamlining the radiopharmaceutical manufacturing process, reducing costs and improving precision. This integration is particularly valuable in identifying optimal dosages and patient-specific treatment regimens, ultimately advancing personalized medicine and reducing adverse effects associated with radiation therapy.
• Expansion of Targeted Cancer Therapies: Cancer remains the primary therapeutic focus for targeted radiopharmaceuticals, with numerous developments aimed at improving treatment outcomes. The rise of radiopharmaceuticals for hard-to-treat cancers, such as neuroendocrine tumors, has expanded the market. Innovations like alpha-particle therapies, which deliver more localized radiation to cancer cells, are gaining attention. This expansion is supported by increasing cancer prevalence and the growing demand for more effective, less invasive treatments, positioning radiopharmaceuticals as key tools in oncology.
• Regulatory Advancements and Approval Process: Regulatory bodies, particularly the FDA and EMA, are streamlining the approval process for radiopharmaceuticals, facilitating quicker market access for new treatments. The U.S. FDA, for example, has provided more flexible pathways for radiopharmaceutical approval, expediting the process for life-saving treatments. This trend is not only reducing the time from research to patient but also fostering innovation in radiopharmaceutical design. Stronger regulatory support is expected to enhance market confidence and further drive the adoption of these therapies globally.
• Global Collaboration and Research Initiatives: Collaborative research efforts between countries and institutions are boosting radiopharmaceutical development. Public-private partnerships, such as those between universities, biotech companies, and healthcare organizations, are accelerating innovation. International research consortia are working on developing novel isotopes, improving production techniques, and enhancing the understanding of radiopharmaceuticals' effectiveness across different patient populations. This global approach is fostering a more diverse pipeline of radiopharmaceuticals, ensuring that patients worldwide benefit from cutting-edge treatments.

These trends are reshaping the targeted radiopharmaceutical market by driving innovation, improving patient outcomes, and reducing treatment costs. The convergence of AI, regulatory advancements, and global collaboration is accelerating the development and availability of targeted therapies, particularly in oncology. As the market grows, these trends will continue to optimize the delivery of personalized, precision-based treatments, ultimately transforming the healthcare landscape for cancer and other complex diseases.

Recent Developments in the Targeted Radiopharmaceutical Market

Several recent developments are transforming the targeted radiopharmaceutical market, from regulatory breakthroughs to technological innovations. These developments are enhancing the precision, availability, and effectiveness of radiopharmaceutical treatments, paving the way for improved patient outcomes and greater market growth.

• FDA Approval of Pluvicto: The approval of Pluvicto (177Lu-PSMA-617) for prostate cancer represents a major milestone for targeted radiopharmaceuticals in oncology. This novel therapy combines a radioactive particle with a molecule that targets prostate cancer cells specifically, reducing damage to healthy tissues. The FDA's approval marks the first of its kind for prostate cancer, offering new hope for patients with advanced stages of the disease. This development opens the door for further innovations in cancer therapies, particularly for cancers with specific molecular targets.
• Development of Alpha-Particle Therapies: Alpha-particle therapies, such as Actinium-225 and Radium-223, have emerged as promising treatments for various cancers. These therapies deliver highly localized radiation, minimizing damage to surrounding healthy tissue and providing a new approach for treating tumors that are resistant to traditional therapies. As research into alpha-particle therapy continues to evolve, the targeted radiopharmaceutical market is expected to see significant growth, especially in the treatment of metastatic cancers.
• Technological Advancements in Imaging and Diagnostics: Advancements in molecular imaging technologies, such as PET and SPECT, have significantly improved the precision of targeted radiopharmaceuticals. These imaging techniques allow for real-time monitoring of the distribution and effectiveness of radiopharmaceuticals, ensuring that they are precisely targeted to the disease site. This development has major implications for personalized medicine, where treatments can be tailored based on the imaging results to maximize therapeutic outcomes.
• Partnerships Between Biotech and Pharmaceutical Companies: Strategic partnerships between biotech firms and major pharmaceutical companies are accelerating the development of targeted radiopharmaceuticals. For instance, collaborations aimed at developing new radiolabeled antibodies for cancer therapy are pushing the boundaries of what is possible in targeted treatments. These alliances allow for sharing resources, expertise, and clinical data, ultimately speeding up the commercialization of innovative radiopharmaceuticals.
• Expanding Production Capacity for Radioisotopes: To meet the growing demand for targeted radiopharmaceuticals, companies are expanding their production capabilities for key radioisotopes, such as Technetium-99m, Lutetium-177, and Iodine-131. This expansion is addressing supply chain challenges and ensuring that sufficient quantities of isotopes are available for clinical use. As production technologies improve, the cost of manufacturing radiopharmaceuticals is expected to decrease, making these therapies more accessible to a broader patient population.

These key developments are revolutionizing the targeted radiopharmaceutical market by improving the accessibility, effectiveness, and precision of treatments. The FDA approvals, advancements in alpha-particle therapies, and growing partnerships between industry players are creating new opportunities for growth. As production capabilities expand and new technologies emerge, the market is poised for continued innovation and a more significant role in global healthcare.

Strategic Growth Opportunities in the Targeted Radiopharmaceutical Market

Targeted radiopharmaceuticals offer significant growth opportunities across various applications. The market is evolving with an increasing focus on oncology, neurology, and diagnostic imaging, driven by both technological advancements and growing patient demand for more personalized treatments.

• Oncology Treatments: Oncology is the largest application for targeted radiopharmaceuticals, and it continues to see the most significant growth. The development of radiopharmaceuticals targeting specific tumor types, such as Lutetium-177 for prostate cancer, is transforming cancer treatment by enabling targeted therapies that reduce damage to healthy tissue. With increasing cancer incidence, the market for radiopharmaceuticals in oncology is expected to expand rapidly, creating opportunities for both new entrants and established companies to innovate.
• Neurology and Neurodegenerative Diseases: Targeted radiopharmaceuticals are increasingly being explored for neurological applications, particularly for neurodegenerative diseases like Alzheimer's. The development of PET radiopharmaceuticals to detect amyloid plaques is already making strides in diagnosis. As research progresses, there is potential for therapeutic radiopharmaceuticals that can target and treat these diseases at the molecular level. This expanding area offers new growth opportunities as the aging population increases globally.
• Cardiology Applications: Radiopharmaceuticals are being developed for the diagnosis and treatment of cardiovascular diseases, such as atherosclerosis. For example, Thallium-201 is already used in cardiac imaging, but new developments are exploring radiopharmaceuticals for targeting heart tissue directly. As cardiovascular disease remains one of the leading causes of death worldwide, targeted radiopharmaceuticals offer significant potential for diagnostic imaging and therapy, especially in personalized treatment approaches.
• Theranostic Applications: The combination of therapy and diagnostics into a single radiopharmaceutical, or theranostics, is gaining traction. By using the same agent for both diagnosis and treatment, theranostics allows for more personalized and precise interventions. This growing segment is driving innovations in oncology and other therapeutic areas, creating substantial growth opportunities as more personalized treatment regimens become available.
• Expansion into Emerging Markets: Emerging markets, particularly in Asia and Latin America, are expected to see strong growth in the targeted radiopharmaceutical sector due to increasing healthcare investments and the rising incidence of cancer. As these markets develop their healthcare infrastructure, the demand for advanced therapies like targeted radiopharmaceuticals is expected to rise significantly. Companies entering these markets early can establish a competitive advantage by providing cost-effective solutions tailored to local healthcare needs.

These growth opportunities are transforming the targeted radiopharmaceutical market by expanding its application base and addressing diverse healthcare needs. From oncology to neurology and emerging markets, the opportunities for innovation and growth are vast. As these opportunities are realized, the market for targeted radiopharmaceuticals is poised to experience robust expansion across multiple therapeutic areas, benefiting patients globally.

Targeted Radiopharmaceutical Market Driver and Challenges

The targeted radiopharmaceutical market is shaped by a combination of technological advances, regulatory changes, economic factors, and market demand. However, these factors present both opportunities and challenges, requiring companies to adapt to evolving conditions while continuing to innovate in the development of new therapies. These drivers and challenges are interconnected and must be addressed to ensure the continued success of the market.

The factors responsible for driving the targeted radiopharmaceutical market include:

1. Technological Advancements: Recent technological innovations in imaging and radiopharmaceutical design are one of the major drivers of the market. Advances in PET and SPECT imaging technologies have enabled precise targeting and tracking of radiopharmaceuticals, ensuring higher treatment accuracy and lower side effects. New isotopes and alpha-particle therapies further expand the possibilities for treating cancer and other diseases. These advancements drive demand for more targeted and personalized treatment options.

2. Increasing Cancer Incidence: The global rise in cancer incidence is one of the key drivers behind the growth of the radiopharmaceutical market. As cancer rates continue to climb, especially in developed countries, the demand for more effective and less invasive treatments is accelerating. Targeted radiopharmaceuticals offer the potential to treat cancers more precisely, reducing side effects and improving outcomes, which makes them an attractive alternative to traditional therapies.

3. Regulatory Support and Approvals: The increasing support from regulatory bodies like the FDA and EMA is crucial in accelerating the adoption of targeted radiopharmaceuticals. Streamlined approval processes and flexible regulatory pathways are allowing new treatments to reach the market more quickly. This regulatory support is helping to drive innovation by encouraging pharmaceutical companies to invest more heavily in the development of novel radiopharmaceuticals.

4. Personalized Medicine Trends: The growing shift toward personalized medicine is a significant market driver. Radiopharmaceuticals allow for tailored treatments based on an individual's unique genetic profile, improving therapeutic outcomes. As precision medicine continues to gain traction, the demand for radiopharmaceuticals that can provide personalized, targeted treatment is expected to grow significantly.

5. Aging Global Population: The global aging population is contributing to increased demand for targeted radiopharmaceuticals, particularly for cancer and neurodegenerative diseases. Older individuals are more prone to conditions that can be treated with radiopharmaceuticals, driving market growth. This demographic shift is expected to continue expanding the patient base for targeted therapies.

Challenges in the targeted radiopharmaceutical market are:

1. High Costs of Production: One of the main challenges facing the market is the high cost of production for radiopharmaceuticals. Manufacturing these complex compounds, particularly the radioisotopes, requires specialized equipment and facilities, which can be expensive. Additionally, the costs of transporting and handling radioactive materials add to the overall expense, limiting access to these treatments in lower-income regions.

2. Limited Availability of Radioisotopes: The production of radioisotopes is often limited by availability and infrastructure. Short-lived isotopes require rapid and specialized manufacturing processes, which can lead to supply shortages. This issue is compounded by geopolitical factors, as the production of key isotopes like Technetium-99m is concentrated in a few regions, posing risks to global supply chains.

3. Regulatory Hurdles and Market Entry Barriers: Although regulatory support is generally improving, navigating the regulatory environment for new radiopharmaceuticals can still be challenging. Each country has its own set of regulations, and achieving international approval can be a time-consuming and expensive process. These hurdles can delay market entry and hinder the rapid commercialization of new radiopharmaceuticals.

The drivers such as technological advancements, increasing cancer rates, and regulatory support are propelling the market forward. However, challenges related to cost, supply limitations, and regulatory complexities must be addressed to ensure sustainable growth. Overcoming these obstacles will be critical for the widespread adoption of targeted radiopharmaceuticals in the future.

List of Targeted Radiopharmaceutical Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies targeted radiopharmaceutical companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the targeted radiopharmaceutical companies profiled in this report include-

• Novartis
• Bayer
• Lantheus
• Institute For Radioelements
• Radiomedix
• Curium Pharma
• Clarity Pharmaceuticals

Targeted Radiopharmaceutical Market by Segment

The study includes a forecast for the global targeted radiopharmaceutical market by type, application, and region.

Targeted Radiopharmaceutical Market by Type [Value from 2019 to 2031]:

• Targeted Therapeutic Radiopharmaceutical
• Targeted Diagnostic Radiopharmaceutical

Targeted Radiopharmaceutical Market by Application [Value from 2019 to 2031]:

• Targeted Therapy
• Targeted Diagnosis

Targeted Radiopharmaceutical Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Targeted Radiopharmaceutical Market

The targeted radiopharmaceutical market has been rapidly evolving, with significant advancements in therapeutic and diagnostic radiopharmaceuticals. These compounds, which combine the precision of targeting specific disease sites with the power of radioactive isotopes, have gained momentum due to their ability to treat conditions like cancer with reduced side effects compared to traditional therapies. This sector is experiencing technological innovation, increased regulatory support, and growing healthcare demand. The United States, China, Germany, India, and Japan are key players driving these developments, each contributing to the global landscape with their unique approaches and market dynamics.

• United States: The U.S. is a global leader in the targeted radiopharmaceutical market, with recent developments driven by increasing FDA approvals and technological advancements. Innovations such as the approval of Pluvicto (177Lu-PSMA-617) for prostate cancer therapy mark significant milestones. Investment in radiopharmaceuticals for oncology is expanding, with numerous clinical trials underway. Additionally, the U.S. is fostering research in theranostics, combining diagnostic and therapeutic properties in a single agent. Major pharmaceutical companies are focusing on developing advanced radiopharmaceuticals, leveraging AI and precision medicine to improve outcomes and reduce side effects.
• China: China is rapidly emerging as a significant player in the targeted radiopharmaceutical market, supported by large-scale investments in both public and private sectors. The country's focus on oncology treatments is reflected in its growing number of clinical trials and regulatory approvals. In particular, China's state-run institutions and biotechnology firms are accelerating research into novel radiopharmaceuticals. The government's "Made in China 2025" initiative is pushing for innovation in the life sciences, which includes radiopharmaceutical production. Additionally, the Chinese healthcare system is embracing personalized medicine, which complements the development of targeted therapies, further driving growth.
• Germany: Germany is home to several leading radiopharmaceutical companies and plays a pivotal role in Europe's radiopharmaceutical market. The country is focused on advancing its nuclear medicine capabilities, particularly in the field of cancer treatment. With a robust regulatory framework, Germany has facilitated the development of radiopharmaceuticals that are now being used in personalized treatments. Key institutions are collaborating on the development of radiopharmaceuticals for both diagnostic and therapeutic purposes, especially in the oncology field. Furthermore, Germany's strong research institutions are pushing boundaries in medical imaging and radioisotope production, which is propelling the market.
• India: India has seen substantial growth in the targeted radiopharmaceutical sector, driven by an increasing demand for affordable cancer therapies. The country is establishing itself as a key hub for radiopharmaceutical production, particularly for diagnostic radiopharmaceuticals. With advancements in production technology, Indian companies are improving the availability of key isotopes like Technetium-99m. Research into new therapeutic applications for targeted radiopharmaceuticals, especially for cancer and neurological disorders, is gaining momentum. The government is also focused on strengthening the regulatory framework, making it easier for new treatments to enter the market and reach patients.
• Japan: Japan remains a leader in the development of advanced targeted radiopharmaceuticals, particularly in nuclear medicine. Recent developments focus on integrating radiopharmaceuticals with diagnostic imaging to offer combined therapy options, a field known as theranostics. Japan's strong collaboration between academia, government, and industry fosters cutting-edge research and innovation. Notably, Japan has pioneered the development of radiopharmaceuticals for rare and complex cancers, such as neuroendocrine tumors. The country's highly advanced healthcare system and its regulatory approach support rapid adoption of new treatments, positioning Japan as a hub for radiopharmaceutical innovation in Asia.

Features of the Global Targeted Radiopharmaceutical Market

• Market Size Estimates: Targeted radiopharmaceutical market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Targeted radiopharmaceutical market size by type, application, and region in terms of value ($B).
• Regional Analysis: Targeted radiopharmaceutical market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the targeted radiopharmaceutical market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the targeted radiopharmaceutical market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the targeted radiopharmaceutical market by type (targeted therapeutic radiopharmaceutical and targeted diagnostic radiopharmaceutical), application (targeted therapy and targeted diagnosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Targeted Radiopharmaceutical Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Targeted Therapeutic Radiopharmaceutical: Trends and Forecast (2019-2031)
• 4.4 Targeted Diagnostic Radiopharmaceutical: Trends and Forecast (2019-2031)

5. Global Targeted Radiopharmaceutical Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Targeted Therapy: Trends and Forecast (2019-2031)
• 5.4 Targeted Diagnosis: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Targeted Radiopharmaceutical Market by Region

7. North American Targeted Radiopharmaceutical Market

• 7.1 Overview
• 7.4 United States Targeted Radiopharmaceutical Market
• 7.5 Mexican Targeted Radiopharmaceutical Market
• 7.6 Canadian Targeted Radiopharmaceutical Market

8. European Targeted Radiopharmaceutical Market

• 8.1 Overview
• 8.4 German Targeted Radiopharmaceutical Market
• 8.5 French Targeted Radiopharmaceutical Market
• 8.6 Spanish Targeted Radiopharmaceutical Market
• 8.7 Italian Targeted Radiopharmaceutical Market
• 8.8 United Kingdom Targeted Radiopharmaceutical Market

9. APAC Targeted Radiopharmaceutical Market

• 9.1 Overview
• 9.4 Japanese Targeted Radiopharmaceutical Market
• 9.5 Indian Targeted Radiopharmaceutical Market
• 9.6 Chinese Targeted Radiopharmaceutical Market
• 9.7 South Korean Targeted Radiopharmaceutical Market
• 9.8 Indonesian Targeted Radiopharmaceutical Market

10. ROW Targeted Radiopharmaceutical Market

• 10.1 Overview
• 10.4 Middle Eastern Targeted Radiopharmaceutical Market
• 10.5 South American Targeted Radiopharmaceutical Market
• 10.6 African Targeted Radiopharmaceutical Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Targeted Radiopharmaceutical Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Novartis
  • Company Overview
  • Targeted Radiopharmaceutical Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Bayer
  • Company Overview
  • Targeted Radiopharmaceutical Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Lantheus
  • Company Overview
  • Targeted Radiopharmaceutical Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Institute For Radioelements
  • Company Overview
  • Targeted Radiopharmaceutical Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Radiomedix
  • Company Overview
  • Targeted Radiopharmaceutical Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Curium Pharma
  • Company Overview
  • Targeted Radiopharmaceutical Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Clarity Pharmaceuticals
  • Company Overview
  • Targeted Radiopharmaceutical Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us